柯萨奇病毒A组16型研究进展

柯萨奇病毒A组16型(CA16)是引起手足口病(HFMD)的主要病原体,与肠道病毒71型(EV71)交替或共同流行;特别是近年在西太平洋地区呈现流行强度高、重症和死亡人数多的特点,已成为该地区的重大公共卫生问题。研发安全有效的疫苗是控制HFMD流行的有效手段。由于EV71所致疾病在重症和死亡病例中所占比例高,对其疫苗研发得到了广泛关注,全病毒灭活疫苗已进入III期临床,有望即将应用于婴幼儿HFMD的防控。EV71疫苗的顺利研发随之也增加了对CA16疫苗研发的迫切性。近年来日本、新加坡以及中国台湾地区逐渐开始关注CA16相关的研究,我国也有多家企业开展CA16疫苗的研发。本文就CA16的病原学,流行病学,实验室诊断,治疗和预防等方面进行了综述。     

干扰素膜蛋白Tet-on系统稳定细胞系的建立及对CA16病毒的抑制作用

通过Tet-on调控系统,构建受多西环素诱导表达干扰素诱导的跨膜蛋白(interferon-induced transmembrane proteins 1/2/3,IFITM1/2/3)基因的HeLa细胞系,并初步探索了IFITM蛋白对柯萨奇病毒A16(CA16)的抑制作用.首先将调控质粒pTet-on转染进入HeLa细胞,通过G418筛选出阳性克隆细胞系,在此细胞系基础上共同转染反应质粒pTRE2-IFITM1/2/3和伴侣质粒pTK-Hyg,通过潮霉素筛选出单克隆细胞系,加入多西环素后利用Western印迹筛选出可诱导表达IFITM1/2/3蛋白的单克隆细胞系.使用实时荧光定量PCR(RT-qPCR)检测发现,多西环素诱导表达的IFITM蛋白对不同感染复数(multiplicity of infection,MOI)的CA16具有明显的抑制作用,其中IFITM 3对CA16的抑制效果最为明显.Tet调控IFITM1/2/3基因表达HeLa细胞系的成功建立,为进一步研究IFITM基因的功能及其抗病毒机理提供了一个理想的细胞模型.     

基于TCID50检测AAV9载体制品感染性滴度的方法

目的:建立一种基于半数组织培养感染剂量(median tissue culture infective dose,TCID₅₀)检测9型腺相关病毒(adeno-associated virus type 9,AAV9)载体制品感染性滴度的方法。方法:利用含AAV2 rep和cap基因的1型单纯疱疹病毒(herpes simplex virus type1,HSV1)做为辅助病毒与梯度稀释的AAV9载体制品共同感染HEK-293细胞,培养48 h后用实时荧光定量PCR(quantitative real-time PCR,qPCR)扩增AAV特异性反向末端重复序列(inverted terminal repeats,ITR),根据阳性及阴性感染孔数,利用Kärber法计算样品的TCID₅₀。结果:采用携带增强绿色荧光蛋白报告基因的AAV9载体制品确定辅助病毒HSV1-rc最佳感染复数(multiplicity of infection,MOI)为5,AAV9-101的感染性滴度为1.6×10⁹ TCID₅₀/mL。结论:对AAV9载体制品进行感染性滴度检测,且具有可重复性。     

甲型肝炎病毒滴度检测方法的优化与验证

目的 对优化后的甲型肝炎病毒滴度检测方法进行验证.方法 分别使用甲型肝炎病毒滴度检测的常规方法(每个细胞培养瓶中加入胰酶消化,收集后经超声破碎、氯仿抽提、聚乙二醇6000浓缩等步骤,收获病毒.滴定期间病毒在35 ℃吸附4h,中间轻摇2次)和优化方法(在每个细胞培养瓶中加入1％ Triton X-1001 mL,置35℃...     

婴幼儿人群中CVA16中和抗体与CVA16手足口病的相关性研究

目的分析婴幼儿中柯萨奇病毒A组16型(coxsackievirus A16,CVA16)中和抗体对CVA16手足口病(hand-foot-mouth disease,HFMD)的预防作用。方法随访2012年1月—2014年1月期间江苏省180名婴幼儿人群(6~<36月龄),主动监测CVA16-HFMD,分别采集0 d、2个月、8个月和24个月的系列血样,并检测其CVA16中和抗体。结果该人群在随访93.9~141 d期间发生了1起CVA16流行,共报告10例CVA16引起的HFMD。中和抗体结果显示,在CVA16流行前(2个月)CVA16中和抗体阴性的153例中,共有10例确诊为CVA16-HFMD(6.5%),49例在流行后(8个月)出现中和抗体阳转(阳转率为32.0%)。而在流行前CVA16中和抗体阳性的27例中,无1例患CVA16-HFMD,8例流行后呈中和抗体4倍及以上升高,占31.7%。10例CVA16-HFMD患者在流行后中和抗体均出现明显升高,较流行前平均升高51.71倍。结论婴幼儿人群中的CVA16中和抗体,可预防CVA16感染导致的HFMD。     

柯萨奇病毒A组16型研究进展

A组16型柯萨奇病毒(Coxsackievirus A16,CVA16)是引起手足口病(Hand,foot and mouth disease,HFMD)的主要病原体之一.近年来,HFMD在亚太地区暴发流行,已经成为重大的公共卫生问题之一.加强对CVA16生物学特征、流行病学特征、临床表现、实验室诊断、防治手段的认识,有助于防控HFMD的蔓延.     

柯萨奇病毒A组16型分子流行病学和疫苗研究进展

柯萨奇病毒A组16型(Coxsackievirus A16,CVA16)是引起手足口病(Hand,foot,and mouth disease,HFMD)的重要致病原,常与另一重要病原体肠道病毒71型(Enterovirus 71,EV-A71)共同或交替流行。该病毒在世界多个国家和地区引起过暴发流行,成为重要的公共卫生问题。CVA16可分为A和B两个基因型;其中基因型B可以分成B1和B2两个基因亚型;B1亚型又可进一步分成B1a、B1b和B1c三个进化分支。基因型A与B2在世界范围内已不再流行;我国大陆分离到的CVA16毒株均属B1a和B1b进化分支。CVA16感染多为自限性轻症,但亦可引起严重的并发症,甚至引起患者死亡。目前尚无针对该病毒的有效药物或治疗手段,研发安全有效的疫苗成为控制该病毒的重要措施。随着EV-A71疫苗三期临床试验的成功完成,CVA16疫苗的研究也显得更加迫切。多家机构正在研究各种类型的CVA16疫苗,包括灭活疫苗、基因工程疫苗及DNA疫苗等。本文就CVA16的分子流行病学及其疫苗研究进展进行了综述。     

中国柯萨奇病毒A组16型部分VP1区序列测定及系统进化分析

利用1999～2004年连续6年从中国深圳及北京地区分离的柯萨奇病毒A组16型(Coxsackievirus A16,Cox．A16)毒株的部分VP1区基因序列进行分析和研究,试图找出中国Cox．A16的种系进化规律和分型依据。6株Cox．A16病毒部分VP1区核苷酸和氨基酸同源性均较高,相互间核苷酸同源性为94．5％～98．0％,氨基酸同源性为97．8％～100％。6株中国分离株与Cox．A16国际参考株相比,部分VP1区核苷酸同源性高于78．2％,氨基酸同源性高于为93．3％。基因系统进化分析表明,中国大陆分离的6株Cox．A16与中国台湾流行株Tainan-5079-98(AF177911),与4株日本分离株、瑞典株及美国株GA95—2095(AF081613)、PA94—5753(AF081628)的关系均较近,核苷酸同源性大于93．3％。了解我国Cox．A16流行株的遗传学背景和种系进化关系,对有效地预防和控制Cox．A16流行有重要意义。     

EV71与CA16双价灭活疫苗诱导小鼠免疫原性研究

目的评价EV71和CA16双价灭活疫苗免疫小鼠诱导的体液免疫和细胞免疫应答。方法分别应用EV71和CA16双价疫苗、EV71和CA16单价疫苗按单针、两针(0,14 d)的程序免疫小鼠,采用细胞病变法检测血清第1针免疫后21 d时中和抗体效价,应用LUMINEX液相芯片技术检测小鼠脾单个核细胞体外经抗原刺激分泌细胞因子的水平。结果双价疫苗与EV71单价疫苗单针、两针免疫相比,EV71中和抗体几何平均值相近(118.8∶84.0;159.5∶156.8,P0.05)。双价疫苗与CA16单价疫苗单针免疫诱导的CA16中和抗体均为阴性;两针免疫CA16中和抗体几何平均值一致(30.0∶26.9,P0.05)。加强免疫7 d后,小鼠脾MNC经EV71抗原刺激,双价疫苗较EV71单价疫苗诱导Th2类细胞因子IL-4、5、6、10和炎症因子TNF-α的分泌水平显著增高(P=0.020,P=0.027,P=0.038,P=0.019,P=0.026);MNC经CA16抗原刺激,双价疫苗与CA16单价疫苗相比诱导细胞因子水平差异无统计学意义(P0.05)。结论双价疫苗可诱导与单价疫苗相似的中和抗体应答水平,并可提高Th2类细胞因子应答,研究为EV71和CA16双价灭活疫苗的研发提供了实验依据。     

Development and characterization of a clinical strain of Coxsackievirus A16 and an eGFP infectious clone

Coxsackievirus A16(CA16) is one of the major causes of hand, foot, and mouth disease(HFMD) worldwide, which is a common illness that affects children. The frequent occurrence of HFMD outbreaks has become a serious public health problem in Asia. Therefore, it is important to understand the pathogenesis and replication of CA16. In this study, a stable infectious c DNA clone of an epidemic strain of Coxsackievirus A16(CA16) was assembled, and subsequently a reporter virus(e GFP-CA16) was constructed by inserting the e GFP gene between the 5'-UTR and the N-terminus of VP4, with the addition of a 2A protease cleavage site(ITTLG) at its C-terminus. This was transfected into Vero cells to generate infectious recombinant viruses. The growth characteristics and plaque morphology, in vitro, in mammalian cells were found to be indistinguishable between the parental and recombinant viruses. Although the e GFP-CA16 showed smaller plaque size as compared to recombinant CA16, both were found to exhibit similar growth trends and EC50 of NITD008. In summary, this stable infectious c DNA clone should provide a valuable experimental system to study CA16 infection and host response. The e GFP-CA16 is expected to provide a powerful tool to monitor e GFP expression in infected cells and to evaluate the antiviral activity of potential antiviral agents in the treatment of CA16 infections.     

肠道病毒71型和柯萨奇病毒A16型多重反转录聚合酶链反应的建立及初步应用

本文旨在建立一种快速、高效的方法检测肠道病毒71型（EV71）和柯萨奇病毒A16型(CA16)的方法,以用于儿童手足口病的病原学监测。通过设计肠道病毒通用引物和CA16与EV71的型特异性引物,建立不同引物浓度配比及两阶段退火温度以提高检测敏感性和特异性的多重反转录聚合酶链反应（RT-PCR）方法,并对首都儿科研究所附属儿童医院2010年3~10月收集的371例手足口病患儿共381份临床标本同时进行病毒分离和核酸检测。结果显示,本研究建立的多重RT-PCR方法对CA16和EV71的最低模板检测浓度分别为5.32 pg/ml和0.64 pg/ml,反应特异度为100%。应用该方法检测381份手足口病临床标本的总阳性率为78.4%,其中CA16与EV71的检测阳性率分别为32.6%和35.8%,二者检测阳性比为1:1.1。以病毒分离为标准,多重RT-PCR对CA16及EV71检测的准确率分别为95.2%和98.6%。因此,本研究新建立的多重RT-PCR方法准确、简便,适用于较大量样本的手足口病病原学监测。2010年引起北京地区儿童手足口病的主要病原为CA16和EV71。     

柯萨奇病毒A组16型衣壳蛋白VP1的原核表达及初步活性测定

目的:原核表达柯萨奇病毒A组16型(CVA16)衣壳蛋白VP1,以便于研制血清学检测试剂。方法:在基因库中钓取CVA16-VP1的全长序列,采用PCR逐步合成法合成其全长基因,测序正确后克隆到表达载体pET28a(+)中,构建重组表达质粒pET28a(+)/VP1,转化大肠杆菌BL21,IPTG诱导表达,利用Ni2+亲和层析柱对重组蛋白进行纯化;建立捕获免疫酶联法检测IgM抗体,检测20份手足口病阳性血清和30份阴性血清,评价重组抗原的灵敏度和特异性;采用CVA16全病毒免疫的抗小鼠血清进行Western印迹。结果:重组CVA16-VP1蛋白在大肠杆菌中获得高效表达;用重组蛋白抗原检测,20份手足口病患儿阳性血清中有4份阳性,其中1份同时为肠道病毒71型(EV71)VP1阳性,30份阴性血清无反应。结论:实现了CVA16-VP1的高效表达,初步结果显示重组蛋白具有较好的抗原性,为柯萨奇病毒A组16型诊断试剂的研究奠定了基础。     

Development of a novel triplex PCR assay for the detection and differentiation of thermophilic species of Campylobacter using 16S-23S rDNA internal transcribed spacer (ITS) region

AIM: Campylobacter species are significantly implicated in human gastrointestinal infections. Of 20 species of Campylobacter, C. jejuni, C. coli and C. lari have been considered as the most important causative agents of human infections. In order to better understand the occurrence and epidemiology of these thermophilic Campylobacter species, an improved and rapid detection method is warranted. A novel triplex polymerase chain reaction (PCR) assay was developed based on the variable 16S-23S rDNA internal transcribed spacer (ITS) region to identify and discriminate between these species in water samples. METHODS AND RESULTS: Campylobacter species-specific primers for C. jejuni, C. coli and C. lari derived from highly variable sequences in the ITS region were used. Specificity of the newly designed primers and PCR conditions were verified using other species of Campylobacter as well as 31 different negative control species. The assay was further validated with 97 Campylobacter cultures from water samples. CONCLUSIONS: The assay was found to be simple, easy to perform, and had a high sensitivity, specificity and reproducibility. It enabled simultaneous detection and differentiation of multiple Campylobacter species in water samples. SIGNIFICANCE AND IMPACT OF STUDY: Use of the newly developed PCR assay, coupled with a previously developed rapid DNA template preparation step, will enable improved detection capabilities for Campylobacter species in environmental matrices.     

An improved LC-MS/MS method for the quantification of prostaglandins E(2) and D(2) production in biological fluids

We report an improved liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay that accurately measures prostaglandins D(2) (PGD(2)) and E(2) (PGE(2)) in cell culture supernatants and other biological fluids. The limit of detection for each prostaglandin was 20 pg/ml (0.20 pg, 0.55 fmol on-column), and the interday and intraday coefficients of variation were less than 5%. Both d(4)-PGE(2) and d(4)-PGD(2) were used as surrogate standards to control for differential loss and degradation of the analytes. Stability studies indicated that sample preparation time should be less than 8h to measure PGD(2) accurately, whereas preparation time did not affect PGE(2) measurement due to its greater stability in biological samples. As an application of the method, PGD(2) and PGE(2) were measured in culture supernatants from A549 cells and RAW 264.7 cells. The human lung alveolar cell line A549 was found to produce PGE(2) but no PGD(2), whereas the murine macrophage cell line RAW 264.7 produced PGD(2) and only trace amounts of PGE(2). This direct comparison showed that COX-2 gene expression can lead to differential production of PGD(2) and PGE(2) by epithelial cells and macrophages. Because PGE(2) is antiasthmatic and PGD(2) is proasthmatic, we speculate that the balance of production of these eicosanoids by epithelial cells and macrophages in the lung contributes to the pathogenesis of chronic obstructive pulmonary disease (COPD), bronchiectasis, asthma, and lung cancer.